文献速递区域麻醉与超声术前评估与围术期医学

抗血栓药物对椎管内麻醉后硬膜外血肿大小及神经功能结局的影响:系统综述

Influence of antithrombotic medication on size and neurological outcome of spinal epidural hematoma after neuraxial anesthesia: a systematic review.
PubMed 文献 · Reg Anesth Pain Med · 2025-01-07

该系统综述纳入304篇文献共345例椎管内麻醉后硬膜外血肿病例,分析抗血栓药物与血肿大小及神经功能结局的相关性。结果显示抗血栓药物与血肿大小无显著关联,但使持续性神经功能缺损风险加倍(OR 2.00,95%CI 1.24-3.23),不遵循指南操作者风险更高(OR 3.42,95%CI 1.71-6.86)。

要点

  • 抗血栓药物不显著增加硬膜外血肿大小,但使持续性神经功能缺损风险加倍。
  • 不遵循指南进行穿刺或拔管者持续性神经功能缺损风险增加3.42倍。
  • 倾向性评分匹配后抗血栓药物与持续性神经功能缺损的关联仍显著(p=0.04)。

核心结论

  • 抗血栓药物与椎管内麻醉后硬膜外血肿大小无显著关联,但使持续性神经功能缺损风险加倍。
  • 不遵循指南进行穿刺或拔管与持续性神经功能缺损风险显著增加相关。

研究设计与样本

  • 系统综述,在PROSPERO注册(CRD42021285833),检索MEDLINE、EMBASE、CENTRAL、Web of Science和Google Scholar(2023年8月),纳入报告椎管内麻醉后硬膜外血肿的研究,共345例病例来自304篇文献。

主要发现

  • 抗血栓药物与血肿大小的关联无统计学意义(OR 0.11,95%CI -0.67至0.89,p=0.78)。
  • 不遵循指南穿刺/拔管与血肿大小的关联无统计学意义(OR 0.13,95%CI -0.92至1.18,p=0.81)。
  • 使用抗血栓药物患者持续性神经功能缺损风险更高(OR 2.00,95%CI 1.24至3.23,p<0.01),倾向性评分匹配后仍显著(p=0.04)。
  • 不遵循指南者持续性神经功能缺损风险增加3.42倍(95%CI 1.71至6.86,p<0.001)。

临床怎么用

  • 临床应重视抗血栓药物使用患者的围术期管理,以降低持续性神经功能缺损风险。
  • 穿刺和拔管操作应严格遵循相关指南,避免不遵循指南的操作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Anticoagulation guidelines were developed to reduce the potential risk of epidural bleeding following neuraxial anesthesia. However, the influence of antithrombotic medication on size of spinal epidural hematoma and neurological outcome is unclear. Therefore, our aim was to analyze whether there is a correlation. METHODS: The study was registered at Prospero (CRD42021285833). A systematic search in MEDLINE, EMBASE, CENTRAL, Web of Science and Google Scholar was conducted in August 2023 for studies reporting spinal epidural hematoma following neuraxial anesthesia. Primary endpoints were segmental extension and neurological outcome. Secondary endpoints were age, sex, body mass index, predisposition, American Society of Anesthesiologists physical status, complicated puncture, multiple punctures, bloody puncture, successful puncture, catheter usage, needle size and worst neurological deficit before treatment. Prespecified multivariate regression and propensity score matching was performed. Publications reporting on more than one patient were critically appraised. RESULTS: A total of 345 cases reported in 304 publications were included. Size of hematoma was not significantly different (antithrombotic medication: OR 0.11, 95% CI (-0.67 to 0.89), p=0.78, 'non-guideline adherent' for puncture/removal: OR 0.13, 95% CI (-0.92 to 1.18), p=0.81). Patients receiving antithrombotic medication were more likely to have persistent neurological deficit (OR 2.00, 95% CI 1.24 to 3.23), p<0.01). Significance persisted after propensity score matching (p=0.04). Patients with non-guideline adherence had a 3.42 higher chance of persistent neurological deficit (95% CI 1.71 to 6.86, p<0.001). DISCUSSION: Antithrombotic medication is not significantly associated with hematoma size; however, the use of antithrombotic medication doubled the risk for persistent neurological deficit after spinal epidural hematoma.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Schieber MR, Schubert AK, Hubner W, et al. Influence of antithrombotic medication on size and neurological outcome of spinal epidural hematoma after neuraxial anesthesia: a systematic review. Reg Anesth Pain Med. 2025. PMID: 38129095. doi:10.1136/rapm-2023-104864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。